Learn more about how TANOVEA-CA1 benefits veterinarians and pet owners.

  • Demonstrated reasonable expectation of effectiveness in clinical studies
  • Can be used in dogs with naive and relapsed/refractory lymphoma
  • Convenient for veterinarians and pet owners
  • Generally well tolerated in clinical studies

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.


CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.


Important Safety Information: TANOVEA®-CA1 is indicated for the treatment of lymphoma in dogs. In clinical trials, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA-CA1. Do not use in West Highland White Terriers and use with caution in other terrier breeds. Owners should take extra care when handling and cleaning up after their dog for five days after treatment. Please see the package insert for full prescribing information, warnings and precautions.